TF and triple-negative breast carcinoma: A similar approach was described in a study reporting the combination of anti-TF CAR-NK cell therapy with chimeric antibody-like homodimer immunoconjugates that also target TF, called ICON and L-ICON, in triple-negative breast cancer (192).